Clinical Trials Browser

Phase 1 × Breast Neoplasms × trastuzumab deruxtecan × Clear all

NCT04704661 2026-03-18

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

BreastGastrointestinalGynecologicHead & NeckSarcoma

Breast Neoplasms, Carcinosarcoma, Colonic Neoplasms, Neoplasm Metastasis, Salivary Gland Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT07137416 2026-03-18

Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer

Phase 1 Recruiting

36 enrolled

Breast

Breast Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT07454668 2026-03-06

Trastuzumab Deruxtecan + Stereotactic Radiosurgery (SRS) in HER2+ Breast Cancer Brain Metastases

Phase 1 Not yet recruiting

20 enrolled

BreastCNS

Brain Neoplasms, Breast Neoplasms, Neoplasm Metastasis, Neoplasms

NCT05633979 2026-01-20

Phase 1b Study of EZH1/2 Inhibitor Valemetostat in Combination With Trastuzumab Deruxtecan in Subjects With HER2 Low/Ultra-low/Null Metastatic Breast Cancer

Phase 1 Active not recruiting

17 enrolled

Breast

Breast Neoplasms

NCT04556773 2025-12-17

DB-08

Phase 1 Active not recruiting

138 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04042701 2025-11-18

DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer

Phase 1 Active not recruiting

115 enrolled

BreastThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT05765851 2025-05-11

A Study of DS-1103a Combination Therapy in Participants With Advanced Solid Tumors

Phase 1 Active not recruiting

78 enrolled

Breast

Breast Neoplasms

NCT03523572 2025-01-27

Trastuzumab Deruxtecan With Nivolumab in Advanced Breast and Urothelial Cancer

Phase 1 Completed

86 enrolled 22 charts

BreastGenitourinary

Breast Neoplasms, Carcinoma, Transitional Cell, Neoplasm Metastasis

NCT06331169 2024-08-30

Anlotinib With Trastuzumab Deruxtecan for Previously Treated HER2-Low Advanced Breast Cancer

Phase 1 Recruiting

42 enrolled

Breast

Breast Neoplasms

NCT03368196 2022-11-03

DS-8201a in Patients With Cancer That Tests Positive for Human Epidermal Growth Factor Receptor 2 (HER2) Protein

Phase 1 Completed

12 enrolled 15 charts

BreastGastrointestinal

Adenocarcinoma, Breast Neoplasms, Neoplasms, Stomach Neoplasms